Source comparison
Comparison: MK-677 Cycling Protocols vs Continuous Growth Hormone Secretagogue Administration
Receptor Sensitivity After 12 Months 85–90% of baseline after each recovery phase 60–70% of baseline with progressive decline 90–95% of baseline with minimal adaptation Micro-cycling preserves the most receptor sensitivity but requires more frequent transition
This comparison does not assign a generated winner or score.
- Receptor Sensitivity After 12 Months
- 85–90% of baseline after each recovery phase
- 60–70% of baseline with progressive decline
- 90–95% of baseline with minimal adaptation
- Micro-cycling preserves the most receptor sensitivity but requires more frequent transitions; 8-week cycling balances efficacy and convenience
- IGF-1 Levels at Month 12 vs Month 1
- 70–80% of initial peak response sustained
- 40–50% of initial peak response
- 80–90% of initial peak response maintained
- Cycling protocols consistently outperform continuous administration by 30–40% in year-long studies
- Appetite Side Effect Intensity
- Resets partially during off-cycles; manageable long-term
- Persists or intensifies regardless of IGF-1 plateau
- Frequent resets minimize cumulative appetite burden
- Off-cycles provide psychological and metabolic relief from appetite stimulation without sacrificing research outcomes
- Protocol Complexity
- Moderate. Requires disciplined on/off tracking
- Low. Single continuous administration schedule
- Higher. More frequent cycle transitions to manage
- Continuous protocols are simpler but sacrifice efficacy; cycling requires structure but delivers superior long-term results
- Suitability for Multi-Year Research
- Excellent. Maintains response across 2–3+ years
- Poor. Efficacy drops significantly after 12–16 months
- Excellent. Indefinite preservation of initial response
- Cycling is essential for any protocol extending beyond one year; continuous use is acceptable only for short-term studies